Ticker Details
Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
IPO Date:	May 1, 2012
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$2.67B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.55 | 2.22%
Avg Daily Range (30 D):	$0.92 | 1.99%
Avg Daily Range (90 D):	$0.87 | 1.83%

Institutional Daily Volume
Avg Daily Volume:	.48M
Avg Daily Volume (30 D):	.73M
Avg Daily Volume (90 D):	.61M

Trade Size
Avg Trade Size (Sh.):	85
Avg Trade Size (Sh.) (30 D):	58
Avg Trade Size (Sh.) (90 D):	53

Institutional Trades
Total Institutional Trades:	4,963
Avg Institutional Trade:	$1.9M
Avg Institutional Trade (30 D):	$3.2M
Avg Institutional Trade (90 D):	$3.55M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.37M
Avg Closing Trade (30 D):	$5.34M
Avg Closing Trade (90 D):	$6.26M
Avg Closing Volume:	69.96K

News

Aug 3, 2026 @ 10:05 PM Why Supernus Pharmaceuticals Stock Topped the Mark... Source: Eric Volkman

Aug 3, 2026 @ 8:57 PM Halper Sadeh LLC is Investigating Whether SUPN, IT... Source: Halper Sadeh Llc

May 6, 2026 @ 9:00 PM Supernus Pharmaceuticals to Participate in the Ban... Source: Na

Feb 23, 2026 @ 11:15 PM Supernus Pharmaceuticals to Participate in March I... Source: Na

Dec 16, 2025 @ 4:35 AM Supernus Stock Is Up 31% This Past Year but Still ... Source: Jonathan Ponciano

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.92	$-1.01	$-.04
Diluted EPS	$-1.92	$-1.01	$-.04
Revenue	$830.44M	$219.06M	$207.71M
Gross Profit	$731.41M	$185.39M	$184.31M
Net Income / Loss	$-109.89M	$-58.37M	$-2.29M
Operating Income / Loss	$-130.46M	$-57.96M	$-8.33M
Cost of Revenue	$99.03M	$33.67M	$23.39M
Net Cash Flow	$36.69M	$-4.92M	$56.42M
PE Ratio